Author

V.-V. Edara

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 2 Research Focus:benchmarking· 1 Research Focus:drug response / drug discovery· 1 Organism:non-human primate· 1

Frequent Co-Authors

A. R. Henry· 3 shared M. Gagne· 3 shared C. R. Ciric· 2 shared D. C. Douek· 2 shared J. Roberts-Torres· 2 shared J. Wrammert· 2 shared K. Floyd· 2 shared L. Hussaini· 2 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

A. R. Henry

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron

M. Gagne, J. I. Moliva, K. E. Foulds, S. F. Andrew, B. J. Flynn, A. P. Werner, D. A. Wagner, I.-T. Teng, B. C. Lin, C. Moore, N. Jean-Baptiste, R. Carroll, S. L. Foster, M. Patel, M. Ellis, , Naisan

This study compares B cell responses and protection against Omicron after boosting vaccinated macaques with mRNA-1273 or mRNA-Omicron vaccines, finding comparable immunity and protection.

bioRxiv · Feb 3, 2022 · PreprintImmunology

mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant

V.-V. Edara, K. E. Manning, M. Ellis, L. Lai, K. M. Moore, S. L. Foster, K. Floyd, M. E. Davis-Gardner, G. Mantus, L. E. Nyhoff, S. Bechnack, G. Alaaeddine, A. Naji, H. Samaha, M. Lee, , M. S. Suthar

This study evaluates the neutralizing activity of mRNA vaccines against the SARS-CoV-2 Omicron variant, showing reduced efficacy after the second dose but improved responses following a third dose.

bioRxiv · Dec 20, 2021Immunology

Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant

V.-V. Edara, L. Lai, M. Sahoo, K. Floyd, M. Sibai, D. Solis, M. W. Flowers, L. Hussaini, C. R. Ciric, S. Bechnack, K. Stephens, E. B. Mokhtari, P. Mudvari, A. Creanga, A. Pegu, , M. Suthar

This study assesses neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant in convalescent and vaccinated individuals, finding it is 6.8-fold more resistant but still neutralizable.

bioRxiv · May 9, 2021 · PreprintImmunology